Press release
curasan AG now sells bone regeneration material in injectable form
CERASORB® Ortho Paste is comprised of fine granules of the proven, fully resorbable, synthetic material CERASORB® M Ortho suspended in a hyaluronic acid hydrogel-matrix. The paste-like product has the advantage that it is pre-packaged in a single-use syringe and does not require any mixing or complicated preparation in order to be applied to the bone defect.
The paste serves as a place holder in the defect and provides ideal conditions for the ingrowth of blood vessels. At the same time, the hydrogel structure of the hyaluronic acid supports the metabolism for new bone generation. In this way new bone grows at the interface with the surrounding healthy bone as the CERASORB® Ortho Paste is resorbed.
The new product, for which a patent has been filed, is expected to be used mainly for filling smaller defects, for example in hand and foot surgery, for smaller bone cysts, for filling of spinal cages, and for minimally invasive sinus lift procedures.
„From the side of the orthopedic and trauma surgeons, there is a strong interest in simple and easy to use materials, particularly for difficult to reach defects“, commented Hans-Dieter Rössler, CEO of curasan AG. „We can now fulfill this wish with our latest development.”
Background information about curasan AG:
Publicly traded curasan AG (ISIN: DE 000 549 453 8) is one of the leading companies in the field of regenerative medicine and specialised on bone and tissue regeneration. The company has developed a future-oriented product pipeline in synthetic bone substitutes and bone regeneration material. Some of these various new developments already have been brought to market, and additional products will follow. These biomaterials will be distributed in different submarkets by well-positioned contractual partners as well as by curasan’s own sales organisation. www.curasan.com
Press contact:
curasan AG
Andrea Weidner
Tel. +49 (0)6027 40 900-51
Fax +49 (0)6027 40 900-39
andrea.weidner@curasan.de
www.curasan.de
fr financial relations gmbh
Jörn Gleisner
Tel. +49 (0)6172 27159-20
Fax +49 (0)6172 27159-69
j.gleisner@financial-relations.de
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release curasan AG now sells bone regeneration material in injectable form here
News-ID: 245477 • Views: …
More Releases from curasan AG
curasan AG: Dental Business Unit acquired as of June 1
Kleinostheim, Germany, June 6, 2013 – curasan AG, Germany, has acquired a large part of the “Oral Regenerative Medicine” division of Riemser Pharma GmbH, Germany, effective June 1, 2013.
curasan AG now owns the marketing and distribution rights for the products covered by the contract and is assuming the sales structures, including the na-tional and international customer base.
As a result of this change, curasan has immediate access to the dental market…
curasan AG commences operations in the European market with the appointment of a …
Kleinostheim, 15.02.2012 – curasan AG, listed in the General Standard (ISIN: DE 000 549 453 8), created a new post on 1st February 2012 in relation to the active expansion of its European sales network in the fields of Orthopaedics and trauma surgery. Mr. Lee McCann BSc Business Administration (North West University of Applied Science, London, U.K.), will be operating as the organisation’s International Sales Director for Orthobiologics with immediate…
curasan AG: Novel bone regeneration material approved for sale in Europe
Kleinostheim, Germany – curasan AG, which is listed in the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8), has received European approval for a novel synthetic bone regeneration material.
Osseolive® is a bioactive, poly-crystalline calcium-alkali-phosphate ceramic, which has a stimulating effect on bone formation as well as on bone mineralisation.
“With Osseolive® emerging from our well-stocked development pipeline, we now have an ideal extension to our tricalcium-phosphate…
curasan AG receives license for Osbone® Dental in the USA
Kleinostheim, Germany, 10th February 2011 - curasan AG, which is listed in the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8), has received FDA certification and, therefore, marketing authorization throughout the USA of the synthetic bone replacement material Osbone® Dental which already has been authorized in the EU as Osbone®.
Osbone® Dental is suitable for utilisation in general bone surgery, particularly in implantology and oral…
More Releases for CERASORB®
Ultimate Chemicals® Featured in Manufacturing Marvels® on The Fox Business Net …
MOORE, OK., Oct. 8, 2021/ -- Ultimate Chemicals® Inc., an integrated manufacturer and supplier of chemicals and related services, is pleased to announce it will be showcased in a broadcast of Manufacturing Marvels® scheduled to air on October 14, 2021 at approximately 9:30-9:44 p.m. EST on The Fox Business Network® (FBN).
Ultimate Chemicals has created their products to help restore surfaces to their optimum surface capability. Non-destructive to the surfaces to…
Sunera Technologies, Inc Joins SAP® PartnerEdge® Delivering SAP® S/4HANA
Sunera Technologies, Inc Joins SAP® PartnerEdge® Delivering SAP® S/4HANA and Intelligent Enterprise to Manufacturing, Consumer Products, Higher education, and research, Industrial machinery and components, Life sciences and Automotive Industries
Chicago, IL, June 10, 2020 – Sunera Technologies, Inc announced that it had joined the SAP® PartnerEdge® program as a Re-sell & Services partner, through which it will resell SAP solutions to midsize organizations in North America. Through this engagement, SuneraTech…
curasan AG receives approval for Cerasorb® M ORTHO in Canada
Kleinostheim, Germany – curasan AG, listed in the General Standard (ISIN: DE 000 549 453 8) has received the certification for the synthetic bone regeneration material Cerasorb® M ORTHO from the Canadian authorities, Health Canada.
“This news has come as a pleasant surprise”, stated Hans Dieter Rössler, CEO. “Since the approval process for medical devices by the Canadian authorities is highly demanding, we were actually expecting the certification some time…
curasan AG: One million units of Cerasorb® produced
Kleinostheim, Germany, 28th April 2010 – The employees of curasan AG awaited the recently produced batch of Cerasorb® M with particular excitement – because amongst this batch was the one millionth bottle ready for sale. Depending on requirements, the bottles contain between 0.5 and 30 grams of the synthetic bone substitute material. The batch was part of a production order placed by Riemser Arzneimittel AG, which has been selling Cerasorb®…
Cerasorb® M used successfully during acetabular cup replacement
curasan AG presented innovative medical products from the Cerasorb® umbrella brand at the 57th annual congress of the Association of South-German Orthopaedic Surgeons (Vereinigung Süddeutscher Orthopäden e. V.) – Report on experiences with the use of Cerasorb® M during revision operations to correct acetabular cup loosening in the hip joint: use of Cerasorb® M for filling of defects successful in 30 older patients – Low risk of infection documented …
American Megatrends Announces AMIBIOS®8 & Aptio®4.x Support for the Intel® Xe …
ATLANTA, GEORGIA - American Megatrends (AMI) is pleased to announce that its AMIBIOS®8 & Aptio®4.x products feature support for the new Intel® Xeon® 5500 Platform.
The Intel® Xeon® 5500 platform combines the Intel® Xeon® Processor 5500 Series with the Intel® 5520 Chipset for embedded, storage, security and communications infrastructure applications in a wide range of form factors. There are four different processor options for this platform with seven year lifecycle support…
